BiomX News

BioMx (PHGE.US) was first covered by Laidlaw & Co. with a buy rating, with a target price of $2.50.

Zhitong FinanceMay 28 10:41

BiomX Analyst Ratings

BenzingaMay 28 10:34

Laidlaw & Co. Initiates Coverage On BiomX With Buy Rating, Announces Price Target of $2.5

BenzingaMay 28 10:36

BiomX Buy Rating Affirmed on Clinical Progress and Strategic Acquisition

TipRanksMay 22 05:46

HC Wainwright & Co. : The BioMX (PHGE.US) rating was confirmed and adjusted from buy to buy, with a target price of $2.00.

Zhitong FinanceMay 21 10:40

BiomX Analyst Ratings

BenzingaMay 21 10:37

HC Wainwright & Co. Reiterates Buy on BiomX, Maintains $2 Price Target

BenzingaMay 21 10:38

BiomX's Strategic Progress and Positive Trials Fuel Buy Rating

TipRanksMay 21 09:55

HC Wainwright & Co. : The BioMX (PHGE.US) rating was confirmed and adjusted from buy to buy, with a target price of $2.00.

Zhitong FinanceApr 22 05:40

BiomX Analyst Ratings

BenzingaApr 22 05:31

Biomx Inc. at a Crossroads: Shareholder Approval Required for Convertible Securities Amid Liquidity Concerns

TipRanksApr 5 01:00

Analysts Are Bullish on These Healthcare Stocks: BiomX (PHGE), Daré Bioscience (DARE)

TipRanksApr 3 13:50

BiomX Analyst Ratings

BenzingaApr 3 10:38

HC Wainwright & Co. Reiterates Buy on BiomX, Maintains $2 Price Target

BenzingaApr 3 10:39

BiomX's Robust Financial Health and Promising Clinical Advancements Bolster Buy Rating

TipRanksApr 3 09:35

CORRECTION: HC Wainwright & Co. Reiterates Buy on BiomX, Adjusts Price Target From $7 To $2

BenzingaMar 8 10:22

BiomX Analyst Ratings

BenzingaMar 7 06:04

BiomX Buy Rating Justified by Merger Synergy, Enhanced Financial Stability, and Promising Clinical Trials

TipRanksMar 7 05:27

Analysts' Opinions Are Mixed on These Healthcare Stocks: CytomX Therapeutics (CTMX), BiomX (PHGE) and Moderna (MRNA)

TipRanksDec 1, 2023 05:30

Buy Rating Affirmed for BiomX as BX004 Shows Strong Efficacy in Phase 2a Cystic Fibrosis Study

TipRanksNov 30, 2023 05:49